In last trading session, Y-Mabs Therapeutics Inc (NASDAQ:YMAB) saw 0.76 million shares changing hands with its beta currently measuring 0.69. Company’s recent per share price level of $6.89 trading at -$0.5 or -6.77% at ring of the bell on the day assigns it a market valuation of $308.60M. That closing price of YMAB’s stock is at a discount of -203.34% from its 52-week high price of $20.90 and is indicating a discount of -0.44% from its 52-week low price of $6.92. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.37 million shares which gives us an average trading volume of 279.75K if we extend that period to 3-months.

For Y-Mabs Therapeutics Inc (YMAB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.46. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.12 in the current quarter.

Y-Mabs Therapeutics Inc (NASDAQ:YMAB) trade information

Upright in the red during last session for losing -6.77%, in the last five days YMAB remained trading in the red while hitting it’s week-highest on Monday, 01/06/25 when the stock touched $6.89 price level, adding 17.39% to its value on the day. Y-Mabs Therapeutics Inc’s shares saw a change of -12.01% in year-to-date performance and have moved -13.55% in past 5-day. Y-Mabs Therapeutics Inc (NASDAQ:YMAB) showed a performance of -32.85% in past 30-days. Number of shares sold short was 3.62 million shares which calculate 13.31 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 24 to the stock, which implies a rise of 71.29% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 24. It follows that stock’s current price would drop -248.33% in reaching the projected high whereas dropping to the targeted low would mean a loss of -248.33% for stock’s current value.

Y-Mabs Therapeutics Inc (YMAB) estimates and forecasts

Statistics highlight that Y-Mabs Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -42.92% of value to its shares in past 6 months, showing an annual growth rate of -34.69% while that of industry is 16.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 4.47% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 26.94M for the same. And 7 analysts are in estimates of company making revenue of 24.37M in the next quarter. Company posted 23.36M and 19.93M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 20.06% during past 5 years.

Y-Mabs Therapeutics Inc (NASDAQ:YMAB)’s Major holders

Insiders are in possession of 12.21% of company’s total shares while institution are holding 72.18 percent of that, with stock having share float percentage of 82.22%. Investors also watch the number of corporate investors in a company very closely, which is 72.18% institutions for Y-Mabs Therapeutics Inc that are currently holding shares of the company. PARADIGM BIOCAPITAL ADVISORS LP is the top institutional holder at YMAB for having 3.87 million shares of worth $46.76 million. And as of 2024-06-30, it was holding 8.8411 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 2.94 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.7126 of outstanding shares, having a total worth of $35.5 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.04 shares of worth $7.17 million or 2.32% of the total outstanding shares. The later fund manager was in possession of 951.95 shares on Oct 31, 2024 , making its stake of worth around $6.56 million in the company or a holder of 2.13% of company’s stock.